These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24433105)

  • 1. An overview of the progress in the treatment of multiple myeloma.
    Kyle RA; Rajkumar SV
    Expert Rev Hematol; 2014 Feb; 7(1):5-7. PubMed ID: 24433105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapies in multiple myeloma.
    El-Amm J; Tabbara IA
    Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Multiple myeloma and other plasma cell dyscrasias].
    Nagy Z
    Magy Onkol; 2016 Jun; 60(2):154-63. PubMed ID: 27275642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple myeloma: treatment evolution.
    San Miguel JF; Mateos MV; Ocio E; Garcia-Sanz R
    Hematology; 2012 Apr; 17 Suppl 1():S3-6. PubMed ID: 22507766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
    McCarthy PL; Einsele H; Attal M; Giralt S
    Expert Rev Hematol; 2014 Feb; 7(1):55-66. PubMed ID: 24471885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel generation of agents with proven clinical activity in multiple myeloma.
    Mateos MV; Ocio EM; San Miguel JF
    Semin Oncol; 2013 Oct; 40(5):618-33. PubMed ID: 24135407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma: is a shift toward continuous therapy needed to move forward?
    Guglielmelli T; Palumbo A
    Expert Rev Hematol; 2015 Jun; 8(3):253-6. PubMed ID: 25582032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.
    Lee HS; Min CK
    Korean J Intern Med; 2016 Sep; 31(5):809-19. PubMed ID: 27604793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance therapy for multiple myeloma.
    McCarthy PL; Palumbo A
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):839-59. PubMed ID: 25212886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma maintenance therapy: a review of the pharmacologic treatment.
    Shank BR; Brown VT; Schwartz RN
    J Oncol Pharm Pract; 2015 Feb; 21(1):36-51. PubMed ID: 24395544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
    Raza S; Safyan RA; Lentzsch S
    Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New treatment strategy of multiple myeloma for cure].
    Murakami H; Handa H
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current strategies for treatment of relapsed/refractory multiple myeloma.
    Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
    Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
    Salvini M; Bonello F; Boccadoro M; Larocca A
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.